The Bevacizumab Skip in Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma

Systemic therapy for unresectable Hepatocellular Carcinoma (u-HCC) has advanced in recent years, particularly immunotherapy. Atezolizumab plus bevacizumab has shown significant survival benefit in u-HCC, and recent AASLD guidelines recommend this regimen as a first-line option.